Synthetically enveloped virus

Abstract

A method of modifying a virus for in vivo delivery to a region of interest includes forming an enveloping composition including a lipid conjugate formed by conjugating at least one lipid with at leastone hydrophilic compound via a linkage which is cleavable under conditions present in the region of interest and combining the virus with the enveloping composition to encompass the virus within theenveloping structure.

Description

[0001] government interest [0002] This invention was made with Government support under Grant No. CA140215 awarded by the National Institutes of Health. The government has certain rights in this invention. [0003] Cross References to Related Applications [0004] This application claims the benefit of U.S. Provisional Patent Application Serial No. 62 / 313,270, filed March 25, 2016, the disclosure of which is incorporated herein by reference. Background technique [0005] The following information is provided to assist the reader in understanding the technology disclosed below and the environments in which it may typically be used. It is not intended that the terms used herein be limited to any particularly narrow interpretation, unless expressly indicated otherwise in this document. References mentioned in this article may help in understanding the technology or its background. The disclosures of all references cited herein are incorporated by reference. [0006] Vir...

AI Technical Summary

Problems solved by technology

Although many of these approaches have been shown to protect viral particles and / or detarget virus from natural target tissues (especially the liver), such approaches often disrupt the evolutionary pathways of viral entry into cells and thus limit viral infection capacity of tumor cells

Use of pH-sensitive cationic polymers mitigates this limitation, but creates toxicity concerns

Although technologies for the modification of viral particles are highly desired, none have entered the clinical setting to date

Images